Posts Feed
Comments Feed

Archive for the 'Cystic Fibrosis' Category

RegeneRx To Develop RGN-457 For Cystic Fibrosis

Oct 3rd 2008Drug InformationCystic Fibrosis

Regenerx Biopharmaceuticals, INC. (AMEX:RGN) announced today that it is seeking a strategic partner to assist in the development of RGN-457 for the treatment of cystic fibrosis (CF). RGN-457 is based on thymosin beta 4 (Tβ4) peptide formulated as an inhaled therapeutic agent to address this patient population. CF is a life-threatening, hereditary disease that impairs the patient’s ability to breathe due to the accumulation of thick and sticky mucus secretions in the airways of the lungs.

More: continued here

No Comments »

New Drug Hope For Cystic Fibrosis Patients

Oct 1st 2008Drug InformationCystic Fibrosis

A new drug therapy may represent a tremendous step forward in the treatment of some 70,000 cystic fibrosis (CF) patients worldwide, Dr David Sheppard from the University of Bristol told an audience at the BA Festival of Science in Liverpool.

More: continued here

No Comments »

Protein Opens Hope Of Treatment For Cystic Fibrosis Patients

Oct 1st 2008Drug InformationCystic Fibrosis

Scientists have finally identified a direct role for the missing protein that leaves cystic fibrosis patients open to attack from lung-damaging bacteria, the main reason most of them die before their 35th birthday, scientists heard at the Society for General Microbiology’s Autumn meeting being held this week at Trinity College, Dublin. “Chronic lung infections are by far and away the biggest problem with the genetic disease cystic fibrosis, affecting almost 90% of patients.

More: continued here

No Comments »

« Prev - Next »

1